Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis

Launched by THE FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIVERSITY · Sep 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Jinghua Weikang Capsules in treating reflux esophagitis, a condition where stomach acid frequently flows back into the esophagus, causing discomfort. The goal is to see if these capsules can help reduce the recurrence of symptoms in patients who have ongoing issues even after standard treatments. Participants will be people aged 18 to 70 who have been diagnosed with reflux esophagitis and have experienced a return of symptoms after receiving standard care.

To be eligible for the trial, participants must sign a consent form and have had a recent endoscopy showing mild forms of reflux esophagitis. They must also meet certain health criteria, ensuring they are fit for the study. Those who join can expect to take Jinghua Weikang Capsules alongside their regular medications while being monitored for any changes in their symptoms. It's important to note that patients with certain severe health conditions or those who have recently taken specific medications may not be able to participate. This trial aims to provide more evidence on the effectiveness of Jinghua Weikang Capsules in maintaining symptom relief for people with reflux esophagitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Sign informed consent.
• • Men and women are not limited
• • Age 18-70 years old
• • Have been diagnosed as reflux esophagitis, and had recurrence after standard treatment ;
• • Upper gastrointestinal endoscopy ( within 1 year ) had reflux esophagitis. In order to facilitate the observation of treatment time and effect, this project selected Los Angeles classification as reflux esophagitis A and B grade.
• • GERD questionnaire reached 8 points in patients with
• • Have appropriate organs and hematopoietic function, according to the following laboratory tests ( within 1 year ) Neutrophil count ( NEUT # ) ≥ 1.5 × 109 / L ; platelet count ≥ 75 × 109 / L ; hemoglobin ≥ 90g / L ; serum total bilirubin ( TBIL ) ≤ 2 times ULN ; alanine aminotransferase ( ALT ), aspartate aminotransferase ( AST ) ≤ 5 times ULN ; serum albumin ≥ 29 g / L ; serum creatinine ≤ 1.5 times the upper limit of normal ( ULN ) or creatinine clearance rate ≥ 50 mL / min.
• • Normal electrocardiogram
• Exclusion Criteria:
• • Patients who received antibiotics, bismuth, H2RA and PPI treatment within two weeks before the first medication ;
• • pregnant or lactating women ;
• • patients with moderate or above depression and mental disorders ;
• • Patients with dysphagia and peptic ulcer such as achalasia, esophageal cancer ;
• • patients with severe liver disease, heart disease, kidney disease, malignant tumor and alcohol dependence ;
• • Those who are allergic to the drugs used in this study ;
• • Patients who participated in other clinical studies within 3 months ;
• • Patients who can not correctly express their complaints and have poor compliance ;
• • There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the results of the study, and subjects who the researchers believe are otherwise unfit to participate in the trial.